Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Phase 2
- Conditions
- Elderly small-cell lung cancer
- Registration Number
- JPRN-C000000134
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
This regimen produced a favorable survival outcome (median: 22.2 months), despite moderate-to-severe toxicity profiles.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Symptomatic brain metastasis Severe active infection Other severe complications Inappropriate condition for this study judged by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Adverse events, overall survival, 1-year survival rate